Carlos Mesía

494 total citations
14 papers, 215 citations indexed

About

Carlos Mesía is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Carlos Mesía has authored 14 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Carlos Mesía's work include Glioma Diagnosis and Treatment (8 papers), Brain Metastases and Treatment (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Carlos Mesía is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Brain Metastases and Treatment (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Carlos Mesía collaborates with scholars based in Spain, France and Peru. Carlos Mesía's co-authors include Miguel Gil‐Gil, Jordi Bruna, Sònia Pernas, Óscar Gallego, Mireia Melé, Luís Manso, Patricia Villagrasa, José Baselga, Meritxell Bellet and Serafín Morales and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Carlos Mesía

13 papers receiving 210 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carlos Mesía Spain 7 99 72 61 58 35 14 215
Ryan Merrell United States 10 146 1.5× 89 1.2× 59 1.0× 51 0.9× 47 1.3× 35 261
Anna M. Tassinari United States 6 96 1.0× 45 0.6× 38 0.6× 48 0.8× 53 1.5× 13 236
María Ángeles Vaz Salgado Spain 9 122 1.2× 125 1.7× 101 1.7× 62 1.1× 81 2.3× 44 354
Shirley Ong United States 8 113 1.1× 92 1.3× 63 1.0× 33 0.6× 66 1.9× 18 215
Víctor Albarrán Spain 10 52 0.5× 155 2.2× 74 1.2× 36 0.6× 68 1.9× 17 284
Diana Isabel Rosero Spain 7 51 0.5× 101 1.4× 57 0.9× 23 0.4× 47 1.3× 11 205
Liana Veresezan France 7 43 0.4× 90 1.3× 54 0.9× 70 1.2× 48 1.4× 16 231
Daniel A. Wattson United States 5 34 0.3× 60 0.8× 53 0.9× 31 0.5× 46 1.3× 6 205
Santino Minichillo Italy 9 110 1.1× 160 2.2× 120 2.0× 137 2.4× 84 2.4× 17 347
Shinobu Yamada Japan 8 53 0.5× 85 1.2× 45 0.7× 37 0.6× 67 1.9× 25 240

Countries citing papers authored by Carlos Mesía

Since Specialization
Citations

This map shows the geographic impact of Carlos Mesía's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Mesía with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Mesía more than expected).

Fields of papers citing papers by Carlos Mesía

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Mesía. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Mesía. The network helps show where Carlos Mesía may publish in the future.

Co-authorship network of co-authors of Carlos Mesía

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Mesía. A scholar is included among the top collaborators of Carlos Mesía based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Mesía. Carlos Mesía is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Hernández, Ainhoa, Ana M Muñoz‐Mármol, Anna Esteve‐Codina, et al.. (2022). In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports. 12(1). 14439–14439. 2 indexed citations
2.
Doménech, Marta, Carlos Mesía, Anna Esteve, et al.. (2021). Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles.. Journal of Clinical Oncology. 39(15_suppl). 2013–2013. 1 indexed citations
3.
Castet, Florian, Noemí Vidal, Cristina Izquierdo, et al.. (2019). Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. Journal of Neuro-Oncology. 143(3). 515–523. 16 indexed citations
4.
5.
Martinez‐García, Maria, Estela Pineda, Sonia Del Barco, et al.. (2016). Feasibility and efficacy of concomitant chemoradiation (Ch-RT) in the management of newly diagnosed elderly glioblastoma (GB) patients: Results from the GLIOCAT study.. Journal of Clinical Oncology. 34(15_suppl). 2045–2045.
6.
7.
Gil‐Gil, Miguel, Meritxell Bellet, Serafín Morales, et al.. (2015). Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Research and Treatment. 151(3). 597–606. 39 indexed citations
8.
Gil‐Gil, Miguel, et al.. (2013). Bevacizumab for the Treatment of Glioblastoma. Clinical Medicine Insights Oncology. 7. 123–35. 76 indexed citations
9.
Pernas, Sònia, Miguel Gil‐Gil, María Ochoa de Olza, et al.. (2012). Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. Breast Cancer Research and Treatment. 134(3). 1161–1168. 14 indexed citations
10.
Gil‐Gil, Miguel, R. de las Peñas, Gaspar Reynés, et al.. (2012). Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-Cancer Drugs. 23(6). 659–665. 32 indexed citations
11.
12.
Alberola, Vicente, Óscar Gallego, Guillermo López-Vivanco, et al.. (2007). P3-061: Erlotinib as single agent in elderly patients (p) with advanced or metastatic NSCLC. Journal of Thoracic Oncology. 2(8). S703–S704. 2 indexed citations
13.
Carles, Joan, Cristina Suárez, Carlos Mesía, et al.. (2006). Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function. Clinical & Translational Oncology. 8(10). 755–757. 16 indexed citations
14.
Solé, Josep María Macias i, Miguel Nogué, J. Montesinos, et al.. (2004). Phase II multicentric study of concurrent chemoradiation (CCR) with biweekly gemcitabine after induction chemotherapy with cisplatin and gemcitabine in unresectable stage III non small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7322–7322. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryan Merrell Breakdown of academic impact, for papers by Anna M. Tassinari Breakdown of academic impact, for papers by María Ángeles Vaz Salgado Breakdown of academic impact, for papers by Shirley Ong Breakdown of academic impact, for papers by Víctor Albarrán Breakdown of academic impact, for papers by Diana Isabel Rosero Breakdown of academic impact, for papers by Liana Veresezan Breakdown of academic impact, for papers by Daniel A. Wattson Breakdown of academic impact, for papers by Santino Minichillo Breakdown of academic impact, for papers by Shinobu Yamada
Rankless by CCL
2026